1. Home
  2. RETO vs PHIO Comparison

RETO vs PHIO Comparison

Compare RETO & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RETO

ReTo Eco-Solutions Inc.

HOLD

Current Price

$2.58

Market Cap

21.9M

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.02

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RETO
PHIO
Founded
1999
2003
Country
China
United States
Employees
48
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.9M
11.2M
IPO Year
2016
2011

Fundamental Metrics

Financial Performance
Metric
RETO
PHIO
Price
$2.58
$1.02
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.00
AVG Volume (30 Days)
7.2K
394.0K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.81
52 Week High
$4.66
$4.19

Technical Indicators

Market Signals
Indicator
RETO
PHIO
Relative Strength Index (RSI) 45.43 46.75
Support Level $2.41 $1.00
Resistance Level $2.80 $1.14
Average True Range (ATR) 0.26 0.07
MACD -0.08 0.00
Stochastic Oscillator 9.39 56.67

Price Performance

Historical Comparison
RETO
PHIO

About RETO ReTo Eco-Solutions Inc.

ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Equipment and technical service segment, and Craft beer segment. The company earns its revenue from the Equipment and technical service segment. Geographically, it derives a majority of its revenue from China.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: